Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K
Links:
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of I…
https://acrabstracts.org/abstract/a-phase-3-randomized-double-blind-multicenter…
16-11-2024